318 related articles for article (PubMed ID: 35168870)
61. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
62. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
medRxiv; 2023 Nov; ():. PubMed ID: 37645804
[TBL] [Abstract][Full Text] [Related]
63. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy.
Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM
J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667
[TBL] [Abstract][Full Text] [Related]
64. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
65. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
[TBL] [Abstract][Full Text] [Related]
66. The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.
Guerra L; Favia M; Di Gioia S; Laselva O; Bisogno A; Casavola V; Colombo C; Conese M
Expert Opin Drug Discov; 2020 Aug; 15(8):873-891. PubMed ID: 32290721
[TBL] [Abstract][Full Text] [Related]
67. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.
Tsai A; Wu SP; Haseltine E; Kumar S; Moskowitz SM; Panorchan P; Shah K
Pulm Ther; 2020 Dec; 6(2):275-286. PubMed ID: 32734574
[TBL] [Abstract][Full Text] [Related]
68. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
Tümmler B
Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
[TBL] [Abstract][Full Text] [Related]
69. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
[TBL] [Abstract][Full Text] [Related]
70. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis.
Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G
J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949
[TBL] [Abstract][Full Text] [Related]
71. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
VanDevanter DR; Zemanick ET; Konstan MW; Ren CL; Odem-Davis K; Emerman I; Young J; Mayer-Hamblett N;
J Cyst Fibros; 2023 Jul; 22(4):652-655. PubMed ID: 37100705
[TBL] [Abstract][Full Text] [Related]
72. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
[TBL] [Abstract][Full Text] [Related]
73. Triple Therapy for Cystic Fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): Desensitization After Skin Rash.
Santos AI; Pacheco J; Cemlyn-Jones J; Gamboa F
Cureus; 2023 Sep; 15(9):e46228. PubMed ID: 37905296
[TBL] [Abstract][Full Text] [Related]
74. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.
Hamai H; Keyserman F; Quittell LM; Worgall TS
J Lipid Res; 2009 Jun; 50(6):1101-8. PubMed ID: 19144995
[TBL] [Abstract][Full Text] [Related]
75. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
76. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
77. Review of CFTR modulators 2020.
Goetz DM; Savant AP
Pediatr Pulmonol; 2021 Dec; 56(12):3595-3606. PubMed ID: 34407318
[TBL] [Abstract][Full Text] [Related]
78. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
O'Carroll M
Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
[TBL] [Abstract][Full Text] [Related]
79. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
[No Abstract] [Full Text] [Related]
80. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
